title: Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
abstract: BACKGROUND
  The purpose of this study was to compare Common Terminology Criteria for Adverse Events (CTCAE), Brock and Chang hearing loss grading in patients with head and neck cancer receiving cis-diamminedichloroplatinum (CDDP). Endpoints were baseline distribution of hearing loss, interobserver consistency, and sensitivity to hearing loss after CDDP treatment.
  
  
  METHODS
  Four hundred sixty single ear audiograms in 110 patients with head and neck cancer were graded. Hearing loss at baseline, interobserver agreement rates, and changes in hearing loss after CDDP were evaluated.
  
  
  RESULTS
  The Chang and Brock tools' baseline hearing loss distribution was concentrated at grade 0 (57% and 41%, respectively), whereas 47%, per the CTCAE, had grade 3 baseline hearing loss. Interobserver agreement was highest for the Brock scale (≥90%) followed by the Chang (≥89%) and CTCAE (≥75%) scales. Detection of change after CDDP was highest for Chang (48%) followed by Brock (45%) and the CTCAE (32%).
  
  
  CONCLUSIONS
  The Brock and Chang tools may be superior to the CTCAE in patients with head and neck cancer receiving CDDP using baseline hearing loss distribution, interobserver agreement, and detection of hearing loss grade change as performance indicators.
authors.affiliation: Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California.
authors.forename: A Dimitrios
authors.initials: AD
authors.lastname: Colevas
authors.affiliation: Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California.
authors.forename: Ruth R
authors.initials: RR
authors.lastname: Lira
authors.affiliation: Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California.
authors.forename: Electra A
authors.initials: EA
authors.lastname: Colevas
authors.affiliation: Department of Health Research and Policy - Biostatistics, Stanford University, Stanford, California.
authors.forename: Philip W
authors.initials: PW
authors.lastname: Lavori
authors.affiliation: Department of Radiation Oncology, Stanford University, Stanford, California.
authors.forename: Cato
authors.initials: C
authors.lastname: Chan
authors.affiliation: Department of Radiation Oncology, Stanford University, Stanford, California.
authors.forename: David B
authors.initials: DB
authors.lastname: Shultz
authors.affiliation: Department of Otolaryngology/Head and Neck Surgery, Stanford University, Stanford, California.
authors.forename: Kay W
authors.initials: KW
authors.lastname: Chang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001299:Audiometry / Q000379:methods; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D034381:Hearing Loss / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin
keywords: adverse event; audiogram; cisplatin; head and neck; hearing loss; ototoxicity
references.citation: Br J Cancer. 1991 Jan;63(1):159-60
references.pmid: 1989659
references.citation: Int J Pediatr Otorhinolaryngol. 2010 Aug;74(8):913-9
references.pmid: 20846503
references.citation: Am J Clin Oncol. 2005 Apr;28(2):143-7
references.pmid: 15803007
references.citation: Ear Hear. 2006 Oct;27(5):526-37
references.pmid: 16957502
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1788-95
references.pmid: 20194861
references.citation: Br J Cancer. 1998 Apr;77(8):1355-62
references.pmid: 9579846
references.citation: J Clin Oncol. 2012 Jul 1;30(19):2408-17
references.pmid: 22547603
references.citation: J Natl Cancer Inst. 2009 Dec 16;101(24):1682-95
references.pmid: 19940282
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8588-96
references.pmid: 16314621
references.citation: Laryngoscope. 2011 Dec;121(12):2649-57
references.pmid: 22109766
references.citation: Pediatrics. 2010 Apr;125(4):e938-50
references.pmid: 20194279
references.citation: J Surg Oncol. 1981;16(2):111-23
references.pmid: 7193262
references.citation: Cancer Treat Rev. 1994 Apr;20(2):191-214
references.pmid: 8156541
references.citation: Med Pediatr Oncol. 1991;19(4):295-300
references.pmid: 2056973
references.citation: Pediatr Blood Cancer. 2013 Feb;60(2):287-92
references.pmid: 23002030